Efficacy of 17α-Hydroxyprogesterone Caproate in Preterm Delivery Prevention

Document Type : Original Article

Authors

1 Associated Professor of Obstetrics and Gynecology, Women's Health Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

2 Resident of Obstetrics and Gynecology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

3 Associated Professor of Biostatics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

Abstract

Introduction: Preterm delivery accounts for preterm labor or birth before 37th weeks of gestation that is the cause of two third of prenatal mortality and one of the problems in obstetrics and hormonal factors are reported to be effective. Progesterone is a placental hormone and effective in maintaining pregnancy. The aim of this study was to evaluate the efficacy of 17α-hydroxyprogesterone caproate in preterm delivery prevention.
 
Methods: This interventional clinical trial was performed on 100 pregnant women who referred to obstetrics clinic of Ghaem hospital affiliated to mashhad university of medical sciences during 2007 to 2008. They were randomly divided into two groups of 50 cases and 50 controls. The case group received intramuscular 250 mg 17α-hydroxyprogesterone caproate injection weekly at 16th up to 37th week of gestational. In control group, routine prenatal cares was performed and then pregnancy outcomes were compared in two groups. Data was analyzed using student t-test and chi square test by SPSS 11 software.
 
Results: Mean gestational age was 36 weeks in case group and 32 weeks in control group. Mean birth weight was 2299 grams in case group and 2695 grams in control group. Ggestational age and birth weight had significant difference in two groups (p<0.05).
 
Conclusion: Weekly administration of 17α-hydroxyprogesterone caproate in pregnant women with history of preterm delivery decrease preterm labor and induced improvement of birth weight.

Keywords

References

1. Gonzalez R. Parentral Administration of Progestrone for Preventing Preterm Birth: RHL
commentary. The WHO Reproductive Health Library;Geneva: World Health Organization;2008 
2. Cunningham FG, Leveno KG, Bloom SL, Has JC, Gillstrap LC, Wenstrom KD. Williams
obstetrics. 22nd ed. New York:McGraw­Hill;2005:855­60,151­60.
 
3. Kramer MS, Demissie K, Yang H, Platt RW, Sauve R, Liston R. The contribution of mild and 
moderate preterm birth to infant mortality. Fetal and Infant Health Study Group of the Canadian 
Perinatal Surveillance System. JAMA 2000 Aug 16;284(7):843­9 
4. Wood NS, Marlow N, Costeloe K, Gibson AT, Wilkinson AR. Neurologic and developmental
disability after extremely preterm birth. EPICure Study Group. N Engl J Med  2000  Aug 
10;343(6):378–84. 5. Spong CY, Meis PJ, Thom EA, Sibai B, Dombrowski MP, Moawad AH, et al. Progesterone for 
prevention of recurrent preterm birth: impact of gestational age at previous delivery. Am J
Obstet Gynecol 2005 Sep;193(3 Pt 2):1127–31.
6. Gilbert WM, Nesbitt TS, Danielsen B. The cost of prematurity: quantification by gestational age
and birth weight. Obstet Gynecol 2003 Sep;102(3):488–92. 7. Petrou  S, Mehta Z, Hockley C, Cook­Mozaffari P, Henderson J, Goldacre M. The impact of 
preterm birth  on hospital admissions and costs during the first 5 years of life. Pediatrics 2003 
Dec;112(6 Pt 1):1290–7. 8. Odibo AO, Stamilio DM, Macones GA, Polsky D. 17alpha­hydroxyprogesterone caproate for the
prevention of preterm delivery: A cost­effectiveness analysis. Obstet Gynecol 2006 Sep;108(3 Pt
1):492­9.
9. Caritis SN, Rouse DJ, Peaceman AM, Sciscione A, Momirova V, Spong C, et al. Prevention of 
preterm birth in triplets using 17α­hydroxyprogesterone caproate: a randomized controlled trial. Obstet Gynecol 2009 Feb;113(2 Pt 1):285­92. 10. Meis PJ, Klebanoff M, Thom E, Dombrowski MP, Sibai B, Moawad AH, et al. Prevention  of 
recurrent preterm delivery by 17α­hydroxyprogesterone caproate. N Engl J Med  2003 Jun 
12;348(24):2379­85. 11. da Fonseca EB, Bittar RE, Carvalho MH, Zugaib M. Prophylactic administration of progesterone
by vaginal suppository to reduce the incidence of spontaneous preterm birth  in  women at
increased risk: a randomized placebo­controlled double­blind study. Am J Obstet Gynecol 2003 
Feb;188(2):419­24. 12. American  College of Obstetricians and Gynecologists. ACOG Committee Opinion. Use of 
progesterone to reduce preterm birth. Obstet Gynecol 2003 Nov;102(5 Pt 1):1115­6.
13. Keirse MJ. Progesterone administration in pregnancy may prevent preterm delivery. Br J Obstet
Gynecol 1990 Feb;97(2):149­54.
14. Daya S. Efficacy of progesterone support for pregnancy in women with recurrent miscarriage. A
meta­analysis of controlled trials. Br J Obstet Gynecol 1989 Mar;96(3):275­80. 15. Magowan BA, Bain M, Juszczak E, McInneny K. Neonatal mortality amongst Scottish preterm
singleton births (1985­1994). Br J Obstet Gynecol 1998 Sep;105(9):1005–10.
16. Martin JA, Hamilton BE, Ventura SJ, Menacker F, Park MM. Births: final data for 2000. Natl
Vital Stat Rep 2002 Feb 12;50(5):1­101.
17. Papiernik, Double blind study of an agent to prevent preterm delivery among women at increased 
risk [in French]. Edition Schering 1970;4(3):65–68. 18.Johnson  JW, Austin  KL, Jones GS, Davis DH, King TM. Efficacy of 17alpha­  hydroxyprogesterone caproate in  the prevention  of premature labor. N Engl J Med 1975 Oct
2;293(4):675–80. 19. Funai EF, Lockwood  CJ, Barss VA. Preterm Birth. Available at: http://www.uptodate.com/ . Accessed Jan 10, 2010.
20. O'Brien JM, Adair CD, Lewis DF, Hall DR, Defranco EA, Fusey S, et al. Progesterone vaginal
gel for the reduction of recurrent preterm birth: primary results from a randomized, double­blind, placebo­controlled trial. Ultrasound Obstet Gynecol 2007 Oct;30(5):687­96. 21. Facchinetti F, Dante G, Venturini P, Paganelli S, Volpe A. 17alpha­hydroxy­progesterone effects
on cervical proinflammatory agents in women at risk for preterm delivery. Am J Perinatol 2008 
Sep;25(8):503­6. 22. How HY, Sibai BM. Progesterone for the prevention  of  preterm birth: indications, when  to 
initiate, efficacy and safety. Ther Clin Risk Manag 2009 Feb;5(1):55­64.
 
23. Fonseca EB, Celik E, Parra M, Singh  M, Nicolaides KH; Fetal Medicine Foundation  Second 
Trimester  Screening. Progesterone and the risk of preterm birth  among  women with  a short
cervix. N Engl J Med 2007 Aug 2;357(5):462­9. 24. Sanchez­Ramos L, Kaunitz AM, Delke I. Progestational agents to prevent preterm birth: a meta­  analysis of randomized controlled trials. Obstet Gynecol 2005 Feb;105(2):273­9.
25. Petrini JR, Callaghan WM, Klebanoff M, Green NS, Lackritz EM, Howse JL, et al. Estimated 
effect of 17  alpha­hydroxyprogesterone caproate on preterm birth in the United States. Obstet
Gynecol 2005 Feb;105(2):267­72. 26. Rouse DJ, Caritis SN, Peaceman AM, Sciscione A, Thom EA, Spong CY, et al. A trial of 17 
alpha­hydroxyprogesterone caproate to prevent prematurity in twins. N Engl J Med 2007 Aug 
2;357(5):454­61. 27. Mackenzie R, Walker M, Armson A, Hannah ME. Progesterone for the prevention  of preterm
birth  among women at increased risk: a systematic review and meta­analysis of randomized 
controlled trials. Am J Obstet Gynecol 2006 May;194(5):1234­42.
28. Goldstein P, Berrier J, Rosen S, Sacks HS, Chalmers TC. A meta­analysis of randomized control
trials of progestational agents in pregnancy. Br J Obstet Gynecol 1989 Mar;96(3):265­74.
29. Hartikainen­Sorri AL, Kauppila A, Tuimala R. Inefficacy of 17  alpha­hydroxprogesterone
caproate in the prevention of prematurity in twin pregnancy. Obstet Gynecol 1980 
Dec;56(6):692­5.

Files

Share

How to cite

Statistics